IL160148A0 - Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor - Google Patents

Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor

Info

Publication number
IL160148A0
IL160148A0 IL16014802A IL16014802A IL160148A0 IL 160148 A0 IL160148 A0 IL 160148A0 IL 16014802 A IL16014802 A IL 16014802A IL 16014802 A IL16014802 A IL 16014802A IL 160148 A0 IL160148 A0 IL 160148A0
Authority
IL
Israel
Prior art keywords
metastasis
recurrence
inhibiting
preventing
pharmaceutical compositions
Prior art date
Application number
IL16014802A
Other languages
English (en)
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of IL160148A0 publication Critical patent/IL160148A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
IL16014802A 2001-08-21 2002-08-16 Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor IL160148A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001249717 2001-08-21
PCT/JP2002/008309 WO2003015826A1 (fr) 2001-08-21 2002-08-16 Compositions pharmaceutiques comprenant des conjugues de polysaccharides permettant l'inhibition des metastases ou la prevention de la recurrence des tumeurs malignes

Publications (1)

Publication Number Publication Date
IL160148A0 true IL160148A0 (en) 2004-07-25

Family

ID=19078678

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16014802A IL160148A0 (en) 2001-08-21 2002-08-16 Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor

Country Status (18)

Country Link
EP (1) EP1418947A1 (fr)
KR (1) KR20040027972A (fr)
CN (1) CN100372570C (fr)
AR (1) AR035137A1 (fr)
AU (1) AU2002328093B2 (fr)
BR (1) BR0212036A (fr)
CA (1) CA2457056C (fr)
HU (1) HUP0401351A3 (fr)
IL (1) IL160148A0 (fr)
MX (1) MXPA04001599A (fr)
NO (1) NO20041194L (fr)
NZ (1) NZ530947A (fr)
PL (1) PL368319A1 (fr)
RU (1) RU2275913C2 (fr)
TW (1) TWI313609B (fr)
UA (1) UA75450C2 (fr)
WO (1) WO2003015826A1 (fr)
ZA (1) ZA200400917B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
FR2914305B1 (fr) * 2007-03-29 2009-07-03 Proteins & Peptides Man Dextran fonctionnalise par des amino-acides hydrophobes.
CN102124096B (zh) 2008-07-16 2014-10-22 儿童医疗中心有限公司 具有微通道的器官模仿装置及其使用和制造方法
KR20190042747A (ko) * 2011-06-02 2019-04-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 생체외 조직 배양 시스템을 위한 방법 및 용도
PL221351B1 (pl) 2012-03-14 2016-03-31 Politechnika Warszawska Sposób otrzymywania nanocząstek polisacharydowych
NZ740948A (en) 2012-10-11 2019-11-29 Daiichi Sankyo Co Ltd Glycinamide derivatives and production methods thereof
ES2782248T3 (es) * 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
KR102275925B1 (ko) 2014-01-31 2021-07-12 다이이찌 산쿄 가부시키가이샤 항-her2 항체-약물 접합체
MY182282A (en) 2015-05-04 2021-01-18 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
CN116059395A (zh) 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
TW201828993A (zh) 2016-12-12 2018-08-16 日商第一三共股份有限公司 抗體－藥物結合物與免疫檢查點抑制劑之組合
BR112019012847A2 (pt) 2017-01-17 2019-12-10 Daiichi Sankyo Co Ltd anticorpo ou fragmento funcional do anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produção de um anticorpo de interesse ou de um fragmento funcional do anticorpo e para produção de um conjugado de anticorpo-fármaco, conjugado de anticorpo-fármaco, composição farmacêutica, fármaco antitumoral, e, método de tratamento de um tumor.
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
JP7366745B2 (ja) 2017-08-31 2023-10-23 第一三共株式会社 抗体－薬物コンジュゲートの改良製造方法
KR102422860B1 (ko) 2017-08-31 2022-07-19 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 신규 제조 방법
TWI825098B (zh) 2018-05-18 2023-12-11 德商葛萊高托普公司 抗ｍｕｃ１抗體
CN109481691A (zh) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 吉西他滨-羧甲基多糖共轭物、制备方法及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69425464T2 (de) * 1993-02-26 2001-05-23 Drug Delivery System Institute, Ltd. Polysaccharidderivat und wirkstoffträger
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (fr) * 1995-12-28 2004-04-20 Kenji Tsujihara Derives de la camptothecine
ATE310538T1 (de) * 1996-04-15 2005-12-15 Asahi Chemical Ind Arzneimittelkomplexe enthaltend taxan- verbindungen oder steroiden
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
CN1058038C (zh) * 1996-12-31 2000-11-01 中国科学院感光化学研究所 低收缩性光固化涂层材料及其制法和用途
KR100581443B1 (ko) * 1998-05-22 2006-05-23 다이이찌 세이야꾸 가부시기가이샤 약물복합체

Also Published As

Publication number Publication date
NO20041194L (no) 2004-03-19
TWI313609B (en) 2009-08-21
AU2002328093B2 (en) 2005-05-05
EP1418947A1 (fr) 2004-05-19
CN100372570C (zh) 2008-03-05
PL368319A1 (en) 2005-03-21
AR035137A1 (es) 2004-04-14
KR20040027972A (ko) 2004-04-01
RU2004108141A (ru) 2005-04-20
WO2003015826A1 (fr) 2003-02-27
HUP0401351A3 (en) 2011-02-28
ZA200400917B (en) 2004-08-25
HUP0401351A2 (hu) 2004-12-28
BR0212036A (pt) 2004-08-17
RU2275913C2 (ru) 2006-05-10
MXPA04001599A (es) 2004-07-08
CA2457056C (fr) 2008-07-22
CN1545423A (zh) 2004-11-10
CA2457056A1 (fr) 2003-02-27
NZ530947A (en) 2006-04-28
UA75450C2 (en) 2006-04-17

Similar Documents

Publication Publication Date Title
IL160148A0 (en) Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor
AU3983201A (en) Compositions and methods for the early diagnosis of ovarian cancer
EP1254267A4 (fr) Compositions et methodes permettant un diagnostic precoce du cancer ovarien
AU2001231199A1 (en) Compositions and methods for the early diagnosis of ovarian cancer
AU2002360769A1 (en) Breast cancer expression profiling
PL354540A1 (en) Drugs for the treatment of malignant tumours
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
EP1709152A4 (fr) Signature moleculaire du suppresseur de tumeur pten
AU9684601A (en) Compositions that inhibit proliferation of cancer cells
EP1476067A4 (fr) Compositions et procedes contre le cancer
AU2002246519A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
EP1461033A4 (fr) Methodes et compositions permettant de diminuer les effets indesirables de la chimiotherapie
AU2002257033A1 (en) Agents and methods for the prevention of initial onset and recurrence of existing cancers
AU2002341749A1 (en) Methods and compositions for inhibiting the proliferation of prostate cancer cells
HUP0402341A3 (en) Compositions containing thiazol-2-ylamines for the treatment of cancer
EP1349485A4 (fr) Compositions et methodes destinees a la therapie et au diagnostic du cancer de l'ovaire
GB0110847D0 (en) Breast cancer detection
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
EP1487983A4 (fr) Prevention de recurrence et de metastase cancereuses
AU2003270202A8 (en) Pharmaceutical compositions useful for the treatment of cancers
HUP0302629A3 (en) Pharmaceutical compositions comprising a combination camptothecin and a stilbene derivative for the treatment of cancer
EP1459754A4 (fr) Medicaments pour la prevention et le traitement du cancer
AU2002332606A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
GB2379444A9 (en) Assay for cancer of the prostate
AU5802200A (en) Agent for gene therapy and for the prevention of metastases, as well as for the gene therapy of tumors